Trial Profile
Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone + rituximab] Vs. R-FC [fludarabine + cyclophosphamide + rituximab]) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation.
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 27 Nov 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Cyclophosphamide; Doxorubicin; Fludarabine; Interferon alpha-2a; Peginterferon alfa-2b; Prednisone; Vincristine
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- 22 Nov 2023 Results investigating how MRD status influenced the efficacy of R-maintenance and how MRD can enable tailored consolidation strategies, published in the Journal of Clinical Oncology
- 05 Dec 2019 Results published in the Journal of Clinical Oncology
- 09 Mar 2017 Planned End Date changed from 1 Dec 2014 to 1 Dec 2018.